vs
Side-by-side financial comparison of Avidia Bancorp, Inc. (AVBC) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
Avidia Bancorp, Inc. is the larger business by last-quarter revenue ($26.8M vs $19.1M, roughly 1.4× NewAmsterdam Pharma Co N.V.). Avidia Bancorp, Inc. runs the higher net margin — 22.9% vs -90.7%, a 113.6% gap on every dollar of revenue. Avidia Bancorp, Inc. produced more free cash flow last quarter ($24.1M vs $-37.8M).
Avidia Bank is an American mutual community bank headquartered in Hudson, Massachusetts. It was founded in 2007 when it was formed by a merger between Hudson Savings Bank and Westborough Bank.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
AVBC vs NAMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.8M | $19.1M |
| Net Profit | $5.3M | $-17.4M |
| Gross Margin | — | — |
| Operating Margin | 33.3% | -186.1% |
| Net Margin | 22.9% | -90.7% |
| Revenue YoY | — | 740.1% |
| Net Profit YoY | — | 55.5% |
| EPS (diluted) | — | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.8M | — | ||
| Q3 25 | $28.0M | — | ||
| Q2 25 | $25.9M | $19.1M | ||
| Q1 25 | $22.9M | — | ||
| Q4 24 | — | $12.8M | ||
| Q3 24 | — | $29.1M | ||
| Q2 23 | — | $8.6M |
| Q4 25 | $5.3M | — | ||
| Q3 25 | $-907.0K | — | ||
| Q2 25 | $3.9M | $-17.4M | ||
| Q1 25 | $-11.6M | — | ||
| Q4 24 | — | $-92.2M | ||
| Q3 24 | — | $-16.6M | ||
| Q2 23 | — | $-42.0M |
| Q4 25 | 33.3% | — | ||
| Q3 25 | -7.0% | — | ||
| Q2 25 | 19.4% | -186.1% | ||
| Q1 25 | -72.0% | — | ||
| Q4 24 | — | -338.5% | ||
| Q3 24 | — | -85.9% | ||
| Q2 23 | — | -461.8% |
| Q4 25 | 22.9% | — | ||
| Q3 25 | -3.2% | — | ||
| Q2 25 | 15.0% | -90.7% | ||
| Q1 25 | -50.5% | — | ||
| Q4 24 | — | -721.7% | ||
| Q3 24 | — | -57.2% | ||
| Q2 23 | — | -486.9% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.05 | — | ||
| Q2 25 | — | $-0.15 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-0.91 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 23 | — | $-0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $275.0M | $739.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $379.0M | $778.5M |
| Total Assets | $2.8B | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $275.0M | — | ||
| Q3 25 | $208.3M | — | ||
| Q2 25 | $592.5M | $739.2M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $834.2M | ||
| Q3 24 | — | $422.7M | ||
| Q2 23 | — | — |
| Q4 25 | $379.0M | — | ||
| Q3 25 | $372.0M | — | ||
| Q2 25 | $191.4M | $778.5M | ||
| Q1 25 | $186.1M | — | ||
| Q4 24 | — | $757.5M | ||
| Q3 24 | — | $378.9M | ||
| Q2 23 | — | $398.4M |
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.8B | — | ||
| Q2 25 | $3.0B | $815.1M | ||
| Q1 25 | $2.7B | — | ||
| Q4 24 | — | $864.6M | ||
| Q3 24 | — | $439.2M | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.4M | $-37.7M |
| Free Cash FlowOCF − Capex | $24.1M | $-37.8M |
| FCF MarginFCF / Revenue | 89.9% | -197.2% |
| Capex IntensityCapex / Revenue | 16.0% | 0.5% |
| Cash ConversionOCF / Net Profit | 5.32× | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.2M | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.4M | — | ||
| Q3 25 | $24.1M | — | ||
| Q2 25 | $-2.3M | $-37.7M | ||
| Q1 25 | $-2.2M | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.5M | ||
| Q2 23 | — | $-31.9M |
| Q4 25 | $24.1M | — | ||
| Q3 25 | $23.3M | — | ||
| Q2 25 | $-3.3M | $-37.8M | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q2 23 | — | $-31.9M |
| Q4 25 | 89.9% | — | ||
| Q3 25 | 83.2% | — | ||
| Q2 25 | -12.8% | -197.2% | ||
| Q1 25 | -16.9% | — | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q2 23 | — | -369.3% |
| Q4 25 | 16.0% | — | ||
| Q3 25 | 3.1% | — | ||
| Q2 25 | 3.7% | 0.5% | ||
| Q1 25 | 7.2% | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 23 | — | 0.1% |
| Q4 25 | 5.32× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.60× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
